Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31503724 | 0.78 | MAPT (0.53) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL1571488 | 0.77 | ERN1 (0.53) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL1570990 | 0.77 | MAPT (0.49) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL1571038 | 0.75 | LCK (0.49) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL2826069 | 0.74 | MAPT (0.55) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL5239537 | 0.74 | MAPT (0.50) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL20328546 | 0.74 | KDM4E (0.54) | MAPTNPSR1POLBGAALCK | |
| SCHEMBL30254383 | 0.73 | MAPT (0.53) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL5660899 | 0.73 | POLB (0.47) | MAPTNPSR1POLBL3MBTL1GAA | |
| SCHEMBL16047636 | 0.73 | MAPT (0.53) | MAPTNPSR1POLBL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-05-14 | — | — | US | disclosed |
| EP-3823970-B1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-03 | — | — | EP | disclosed |
| CN-112771046-B | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-06-03 | — | — | US | disclosed |
| EP-3823970-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-05-26 | — | — | EP | disclosed |
| CN-112771046-A | Other substituted triazoloquinoxaline derivatives | 格吕伦塔尔有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2021-04-20 | — | — | US | disclosed |
| WO-2020016452-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
| WO-2020016452-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | KASUMA PARTNERS INC. (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | KASUMA PARTNERS INC. (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | KASUMA PARTNERS INC. (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3178810-A1 | CONDENSED HETEROCYCLIC COMPOUND | Kasuma Partners Inc. (JP) | 2017-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, GRK5, NR3C2 | MAPT 4633/4885NPSR1 234/4885POLB 2965/4885 |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | MAPT 4633/4885NPSR1 234/4885POLB 2965/4885 |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | MAPT 4633/4885NPSR1 234/4885POLB 2965/4885 |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | MAPT 4633/4885NPSR1 234/4885POLB 2965/4885 |
| US-20170298081-A1 | CONDENSED HETEROCYCLIC COMPOUND | APOB, NPC1, NPC1L1 | MAPT 3961/4885NPSR1 523/4885POLB 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.